| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Bortezomib | gCSI | pan-cancer | AAC | -0.012 | 0.8 |
| mRNA | NSC95397 | CTRPv2 | pan-cancer | AAC | 0.0066 | 0.8 |
| mRNA | tanespimycin:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0064 | 0.8 |
| mRNA | Vorinostat | gCSI | pan-cancer | AAC | 0.0098 | 0.8 |
| mRNA | salermide | CTRPv2 | pan-cancer | AAC | -0.0089 | 0.8 |
| mRNA | C6-ceramide | CTRPv2 | pan-cancer | AAC | -0.0073 | 0.8 |
| mRNA | BRD-K41334119 | CTRPv2 | pan-cancer | AAC | -0.015 | 0.8 |
| mRNA | ML210 | CTRPv2 | pan-cancer | AAC | 0.0064 | 0.8 |
| mRNA | SMER-3 | CTRPv2 | pan-cancer | AAC | -0.0074 | 0.8 |
| mRNA | procarbazine | CTRPv2 | pan-cancer | AAC | -0.0075 | 0.9 |